Avalo Therapeutics (AVTX) Return on Sales (2016 - 2025)

Avalo Therapeutics' Return on Sales history runs 10 years deep, the most recent figure standing at 2.33% for Q4 2025.

• Quarterly Return on Sales fell 48.0% year-over-year to 2.33% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.57% (down 77.0% YoY) and the FY2025 annual result came in at 13.26%, down 1247.0% from the prior year.
• Return on Sales was 2.33% for Q4 2025 at Avalo Therapeutics, down from 2.26% in the prior quarter.
• Across five years, Return on Sales topped out at 0.93% in Q3 2024 and bottomed at 2.33% in Q4 2025.
• A 5-year average of 0.45% and a median of 0.13% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales jumped 115 bps — and 2025, when it slumped 319 bps.
• Avalo Therapeutics' Return on Sales stood at 0.0% in 2021, then jumped by 99 bps to 0.0% in 2022, then tumbled by 382254 bps to 0.14% in 2023, then plunged by 1187 bps to 1.84% in 2024, then dropped by 26 bps to 2.33% in 2025.
• Business Quant data shows AVTX's Return on Sales at 2.33% in Q4 2025, 2.26% in Q3 2025, and 1.84% in Q4 2024.